Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors.

doi:10.1016/j.neurobiolaging.2012.12.008

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors.

Neurobiology of aging - 1 Jun 2013

Martinelli-Boneschi Filippo, Giacalone Giacomo, Magnani Giuseppe, Biella Gloria, Coppi Elisabetta, Santangelo Roberto, Brambilla Paola, Esposito Federica, Lupoli Sara, Clerici Francesca, Benussi Luisa, Ghidoni Roberta, Galimberti Daniela, Squitti Rosanna, Confaloni Annamaria, Bruno Giuseppe, Pichler Sabrina, Mayhaus Manuel, Riemenschneider Matthias, Mariani Claudio, Comi Giancarlo, Scarpini Elio, Binetti Giuliano, Forloni Gianluigi, Franceschi Massimo, Albani Diego

Abstract excerpt

We conducted a genome-wide association study in a cohort of 176 Italian Alzheimer's disease (AD) patients with extreme phenotype of response to cholinesterase inhibitors. Patients were classified into responders in case of positive, stable, or ≤1 worsening of mini-mental state examination score and into nonresponders if >3 points worsening during a median follow-up of 0.85 years of treatment. Forty-eight...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Alzheimer Disease

Share to Cholinesterase Inhibitors

Share to Cohort Studies

Share to Follow-Up Studies

Share to Genome-Wide Association Study

Share to Pharmacogenetics

Source

Open in PubMed

Identifiers

PMID: 23374588
DOI: 10.1016/j.neurobiolaging.2012.12.008

Genes

NBEA
PRKCE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors.PMID 23374588Read ↗

Pharmacogenomics for the treatment of dementia.Semantic proximity Read ↗

Effect of genetic polymorphisms on Alzheimer’s disease treatment outcomes: an updateSemantic proximity Read ↗

Mendelian Randomization Identified CHRNE as a Potential Drug Target for Alzheimer’s diseaseSemantic proximity Read ↗

Pharmacogenomics in Alzheimer's disease.Semantic proximity Read ↗

Pharmacogenetic Considerations in the Treatment of Alzheimer’s DiseaseSemantic proximity Read ↗

CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients.Semantic proximity Read ↗

Exploratory analysis of seven Alzheimer's disease genes: disease progression.Semantic proximity Read ↗

Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimers Disease PharmacogeneticsSemantic proximity Read ↗

Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer's disease.Semantic proximity Read ↗

Drug Response of Iranian Alzheimer's Patients to Rivastigmine Concerning Their Genotype for VDR rs11568820 and MTHFR C677T Variants: A Pharmacogenetic and Association Study.Semantic proximity Read ↗

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).Semantic proximity Read ↗

CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.